Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company concentrate on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is presently developed for stage IV colorectal cancer and is slated to start first-in-human trials later this month. Boehringer Ingelheim aims to develop new therapies by combining equity from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform.
The whole transaction may amount up to EUR 325 million and is comprised of upfront payment in addition to contingent clinical, improvement and regulatory milestones plus as much as EUR 100 million if certain commercial milestones are hit.
Boehringer Ingelheim’s Cancer Immunology group is constructed to find therapies that have interaction triggering of immune responses against non-inflamed, “cold” tumors, which represent a large group of cancer types refractory to many treatments, together with checkpoint inhibitor medication. Immune targeting of cold tumors is a selected challenge. AMAL’s KISIMA vaccine expertise, designed to stimulate potent immune responses, is a promising therapeutic choice for patients with these type of cancers.
The AMAL acquisition, along with 2018 acquisition of Vira Therapeutics (Vira-T) and in-license of OSE Immunotherapeutics’ SIRP-alpha targeting antibody, considerably strengthens Boehringer Ingelheim’s strategic focus on immune cell-directed therapies. By combining its world-class in-house research and improvement with that of highly innovative biotechnology companies, Boehringer Ingelheim is developing innovative immuno-oncology therapies and accelerating the delivery of the next era of cancer treatments.
AMAL is headquartered on the medical campus of the University of Geneva, with financial backing from a syndicate of each company and institutional traders, together with the Boehringer Ingelheim Enterprise Fund and High-Tech Gründerfonds because of the initial seed investors. Further investments had been supplied by VI Companions, Helsinn Investment Fund, BioMed Partners and Schroder Adveq. AMAL’s expertise platform and derived products are protected by a broad portfolio of patents and licenses.